Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
Work
Year: 2021
Type: article
Institutions Agostino Gemelli University Polyclinic, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Charité - Universitätsmedizin Berlin, General University Hospital in Prague, Gynecologic Oncology Group +4 more
Cites: 16
Cited by: 20
Related to: 10
FWCI: 1.927
Citation percentile (by year/subfield): 83.45
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: closed